Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target

Gene: FYN

Summary for FYN

Gene information	Gene symbol	FYN
	Ensembl ID	ENSG00000010810
	Entrez ID	2534
	Gene name	FYN proto-oncogene, Src family tyrosine kinase
	Synonyms	MGC45350\|SLK\|SYN
	Gene type	protein_coding
	UniProtAcc	P06241

Top

Dataset with differentially expressed gene: FYN

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD4+ T cells	0.276714	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD8+ T cells	0.292503	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	NK cells	0.376754	4.09e-33
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-0.450797	4.69e-42
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-0.344487	0.00e+00
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	0.275078	7.26e-04
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD8+ T cells	-0.298641	4.81e-32
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	CD8+ T cells	-0.340536	3.92e-23
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	CD8+ T cells	-0.314973	1.00e-06
GSE131984_JQ1Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + palbociclib	NA	Malignant cells	0.261821	1.87e-19
GSE115251	Kelly cell line	Cell line	Neuroblastoma	Neuroblastoma	Targeted therapy	TAE684	NA	Malignant cells	0.696363	0.00e+00

Top

Expression of FYN in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to FYN

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Gene symbol	Mechanism
FYN	Regulation by the Disease Microenvironment
FYN	Unusual Activation of Pro-survival Pathway

Page: 1

Top

MicroRNAs (miRNA) regulating FYN

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
FYN	hsa-miR-10523-5p	98.1476	NM_002037
FYN	hsa-miR-4495	95.8464	NM_002037
FYN	hsa-miR-4700-3p	95.8045	NM_002037
FYN	hsa-miR-1251-3p	94.3407	NM_002037
FYN	hsa-miR-8086	93.9538	NM_002037
FYN	hsa-miR-3690	93.7262	NM_002037
FYN	hsa-miR-6871-3p	92.5512	NM_002037
FYN	hsa-miR-380-3p	91.0076	NM_002037
FYN	hsa-miR-5000-3p	90.2119	NM_002037
FYN	hsa-miR-4436a	90.2119	NM_002037
FYN	hsa-miR-8087	89.5613	NM_002037
FYN	hsa-miR-211-3p	89.5468	NM_002037
FYN	hsa-miR-150-3p	89.187	NM_002037
FYN	hsa-miR-190a-3p	87.5752	NM_002037
FYN	hsa-miR-5011-5p	86.9372	NM_002037
FYN	hsa-miR-130b-3p	86.6941	NM_002037
FYN	hsa-miR-656-3p	86.4941	NM_002037
FYN	hsa-miR-4717-5p	86.407	NM_002037
FYN	hsa-miR-454-3p	85.6585	NM_002037
FYN	hsa-miR-548aj-3p	85.336	NM_002037
FYN	hsa-miR-548x-3p	85.336	NM_002037
FYN	hsa-miR-548j-3p	84.5405	NM_002037
FYN	hsa-miR-548ae-3p	84.5405	NM_002037
FYN	hsa-miR-548am-3p	84.5405	NM_002037
FYN	hsa-miR-548aq-3p	84.5405	NM_002037
FYN	hsa-miR-548ah-3p	84.5405	NM_002037
FYN	hsa-miR-6750-3p	84.1711	NM_002037
FYN	hsa-miR-381-3p	84.0692	NM_002037
FYN	hsa-miR-300	84.0692	NM_002037
FYN	hsa-miR-4251	83.3125	NM_002037
FYN	hsa-miR-130a-3p	83.0358	NM_002037
FYN	hsa-miR-4295	83.0358	NM_002037
FYN	hsa-miR-301b-3p	83.0358	NM_002037
FYN	hsa-miR-3666	83.0358	NM_002037
FYN	hsa-miR-301a-3p	83.0358	NM_002037
FYN	hsa-miR-361-3p	82.8619	NM_002037
FYN	hsa-miR-6835-3p	82.1689	NM_002037
FYN	hsa-miR-130a-5p	81.8924	NM_002037
FYN	hsa-miR-16-1-3p	81.5794	NM_002037
FYN	hsa-miR-3679-3p	80.152	NM_002037

Page: 1

Top

Motifs and transcription factors (TFs) regulating FYN

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
FYN	jaspar__MA1122.1	TFDP1 (directAnnotation).
FYN	hdpi__RARA	RARA (directAnnotation).
FYN	jaspar__MA0185.1	DEAF1 (inferredBy_Orthology).
FYN	hdpi__FEZF2	FEZF2 (directAnnotation).
FYN	hocomoco__FEV_HUMAN.H11MO.0.B	FEV (directAnnotation).
FYN	cisbp__M00775	ZBTB1 (inferredBy_Orthology).
FYN	hdpi__PDLIM5	PDLIM5 (directAnnotation).
FYN	transfac_pro__M03846	SMAD5 (directAnnotation).
FYN	hdpi__HTATIP2	HTATIP2 (directAnnotation).
FYN	metacluster_15.1	E2F4; E2F4; E2F4; E2F4; E2F7; ZFP69B (directAnnotation). E2F4 (inferredBy_Orthology).
FYN	transfac_pro__M01240	GTF2IRD1 (directAnnotation).
FYN	hdpi__OTUD4	OTUD4 (directAnnotation).
FYN	transfac_pro__M02844	BCL6B (inferredBy_Orthology).

Page: 1 2 3

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

Target name	Drug name	Drug ID	Drug type
FYN	"Dasatinib"	DB01254	small molecule
FYN	"Fostamatinib"	DB12010	small molecule
FYN	"Triglyme"	DB02078	small molecule
FYN	"Zotiraciclib"	DB16656	small molecule

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."